Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 17, Number 6—June 2011

Cefepime-Resistant Pseudomonas aeruginosa

Ehimare Akhabue, Marie Synnestvedt, Mark G. Weiner, Warren B. Bilker, and Ebbing LautenbachComments to Author 
Author affiliations: Author affiliation: University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA

Main Article

Table 2

Multivariable model of risk factors for cefepime-resistant Pseudomonas aeruginosa infection, Philadelphia, PA, USA, 2001–2006*

Variable Unadjusted OR Adjusted OR (95% CI) p value
Prior use of extended-spectrum cephalosporin 2.87 2.18 (1.57–3.04) <0.001
Prior use of extended-spectrum penicillin 2.99 1.91 (1.22–2.99) 0.005
Prior use of quinolone 2.61 1.96 (1.38–2.78) <0.001
Prior use of carbapenem 2.74 1.70 (0.90–3.21) 0.10
Transfer from outside facility 1.85 1.49 (1.09–2.04) 0.01
Length of hospital stay before culture NA 1.00 (0.99–1.01)† 0.81

*OR, odds ratio; CI, confidence interval; NA, not applicable. No substantive changes were found when above analyses were limited to bloodstream isolates only.
†Odds associated with each 1-day increase in hospital stay.

Main Article

Page created: September 01, 2011
Page updated: September 01, 2011
Page reviewed: September 01, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.